Grant: CIHR Fellowship
University of Toronto
$135,000.00
Harnessing tissue-specific expression of E3 ligases for selective protein degradation in cancer
FY 2021-22
Summary
The existing arsenal of cancer therapies comprises drugs that act mostly by modifying the function of their targets with little or no impact on their protein levels. A novel approach known as targeted protein degradation has recently emerged whereby drugs can be designed to reduce the protein levels of their respective targets. These drugs do so by hijacking the cellular waste disposal machinery that precisely tags cellular proteins for degradation. Proteolysis targeting chimeras (PROTACs) is a major class of such targeted protein degraders that can be customized to efficiently eliminate targets critical for cancer growth. Through their two-headed structure, PROTACs serve as matchmakers that bring protein-degrading enzymes close to their cellular targets to initiate their disposal. We propose to develop smart PROTACs that act as enhanced precision missiles in cancers that concomitantly express high levels of the degradative enzymes and their targets. In our project, we will focus on small-cell lung cancer (SCLC) and acute lymphoblastic leukemia (ALL) that express high levels of the degradative enzyme DCAF16 and the epigenetic target EZH2 that supports the growth of these cancers. This project will provide a proof of concept for developing smart expression-guided PROTACs and help identify better therapeutic options for SCLC and ALL.
Department
Program
CIHR Fellowship
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
455096
Name
Barghout Samir
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Harnessing tissue-specific expression of E3 ligases for selective protein degradation in cancer
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Acute Lymphoblastic Leukemia; Cancer Therapy; Dcaf16; E3 Ligases; Epigenetics; Ezh2; Protacs; Small-Cell Lung Cancer; Targeted Protein Degradation; Ubiquitin System
Abstract
The existing arsenal of cancer therapies comprises drugs that act mostly by modifying the function of their targets with little or no impact on their protein levels. A novel approach known as targeted protein degradation has recently emerged whereby drugs can be designed to reduce the protein levels of their respective targets. These drugs do so by hijacking the cellular waste disposal machinery that precisely tags cellular proteins for degradation. Proteolysis targeting chimeras (PROTACs) is a major class of such targeted protein degraders that can be customized to efficiently eliminate targets critical for cancer growth. Through their two-headed structure, PROTACs serve as matchmakers that bring protein-degrading enzymes close to their cellular targets to initiate their disposal. We propose to develop smart PROTACs that act as enhanced precision missiles in cancers that concomitantly express high levels of the degradative enzymes and their targets. In our project, we will focus on small-cell lung cancer (SCLC) and acute lymphoblastic leukemia (ALL) that express high levels of the degradative enzyme DCAF16 and the epigenetic target EZH2 that supports the growth of these cancers. This project will provide a proof of concept for developing smart expression-guided PROTACs and help identify better therapeutic options for SCLC and ALL.
Competitiondate
202110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Barghout, Samir
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~